NASDAQ$MLAB
Mesa Laboratories Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Reported strong revenue growth driven by organic growth and the acquisition of GKE, with operating income significantly increasing and strategic investments continuing.
Mesa Labs reported a 17.5% increase in revenues, driven by 12.6% organic growth and a 4.9% inorganic contribution from GKE. Operating income saw a substantial increase of 8,725%. However, the company experienced a net loss due to unrealized foreign currency losses and interest expense. Non-GAAP core organic revenues grew by 13.2%, and AOI increased by 21.2%.
- Revenues increased by 17.5% driven by organic growth and the acquisition of GKE.
- Operating income increased significantly by 8,725%.
- Non-GAAP core organic revenues grew by 13.2%.
- AOI excluding unusual items increased by 13.3%.
Headline financials
Revenue & EPS history
Mesa Labs · Revenue · Quarterly
$62.8M
Revenue by segment
Mesa Labs · $63.7M total across 4 segments · Q4 2026
- Sterilization and Disinfection Control$29.1M—45.7%
- Calibration Solutions$13.6M—21.3%
- Clinical Genomics$12.2M—19.1%
- Biopharmaceutical Development$8.85M—13.9%
Forward guidance
Solid sales funnels and a backlog build in 3Q25 will enable year over year core revenues growth in 4Q25. The company anticipates adapting to new policies and market shifts, including the recent appreciation of the US dollar, and rising recession risk in Europe.
Tailwinds
- Solid sales funnels expected to drive core revenue growth.
- Backlog build in 3Q25 supports future revenue.
- Strong operating leverage profile.
- Continued investment in strategic initiatives.
- Acquisition of GKE delivered first twelve months of full ownership revenues >10% higher than initial expectations.
Headwinds
- Potential need to adapt to new policies in the USA.
- Recent appreciation of the US dollar.
- Rising recession risk in Europe.
- Operating results tend to change quickly in response to market conditions.
- Ongoing headwinds from China and continued disruption to the U.S. Laboratory Developed Test (“LDT”) market
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
+0.1%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
35 / 64 earnings
Positive
+26.6%
Q2 2023
Best reaction
-24.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | — | — | — | |
| Q3 2026 | +8.7% | +15.9% | +8.8% | |
| Q2 2026 | +2.1% | +6.7% | +3.7% | |
| Q1 2026 | -24.9% | -16.0% | -15.9% | |
| Q4 2025 | -9.3% | -13.5% | -12.8% | |
| Q3 2025 | +2.5% | +10.3% | +3.2% | |
| Q2 2025 | -11.4% | -16.2% | -7.6% | |
| Q1 2025 | +5.8% | +11.8% | +13.4% | |
| Q4 2024 | +13.3% | +5.5% | -3.4% | |
| Q3 2024 | +2.0% | -0.2% | +18.9% | |
| Q2 2024 | +0.1% | -8.8% | +2.0% | |
| Q1 2024 | +8.0% | +10.3% | +11.4% | |
| Q4 2023 | -2.2% | -7.7% | -11.7% | |
| Q3 2023 | -7.4% | -8.6% | -13.5% | |
| Q2 2023 | +26.6% | +31.2% | +39.1% | |
| Q1 2023 | -5.5% | -10.7% | -23.5% | |
| Q4 2022 | -3.7% | -2.7% | -6.1% | |
| Q3 2022 | -3.9% | -2.0% | -5.8% | |
| Q2 2022 | +4.0% | +1.4% | -0.1% | |
| Q1 2022 | +0.4% | -1.4% | -3.8% | |
| Q4 2021 | +4.7% | +6.4% | +9.6% | |
| Q3 2021 | +0.9% | -0.4% | -5.2% | |
| Q2 2021 | -0.4% | +2.7% | +2.1% | |
| Q1 2021 | +2.0% | -1.5% | -1.4% | |
| Q4 2020 | -5.7% | -6.5% | -18.6% | |
| Q3 2020 | -7.2% | -2.4% | -13.9% | |
| Q2 2020 | -0.2% | -4.7% | +3.3% | |
| Q1 2020 | +6.6% | +7.0% | -7.3% | |
| Q4 2019 | -21.1% | -19.3% | -2.3% | |
| Q3 2019 | +0.6% | +3.4% | +2.2% | |
| Q2 2019 | +0.9% | +3.0% | +20.4% | |
| Q1 2019 | -2.7% | -0.3% | +3.5% | |
| Q4 2018 | +16.3% | +15.4% | +31.3% | |
| Q3 2018 | -5.1% | -14.2% | -8.0% | |
| Q2 2018 | -17.2% | -19.7% | -19.7% | |
| Q1 2018 | +5.2% | +1.6% | -2.5% | |
| Q4 2017 | -6.5% | -13.3% | -12.3% | |
| Q3 2017 | +6.4% | +1.4% | +5.2% | |
| Q2 2017 | -1.3% | -0.8% | -1.1% | |
| Q1 2017 | -4.3% | -10.4% | -10.5% | |
| Q4 2016 | +12.7% | +26.5% | +23.1% | |
| Q3 2016 | -4.8% | — | — | |
| Q2 2016 | +1.9% | — | — | |
| Q1 2016 | +13.3% | — | — | |
| Q4 2015 | +2.1% | — | — | |
| Q3 2015 | +0.8% | — | — | |
| Q2 2015 | +10.4% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -4.0% | — | — | |
| Q3 2013 | -0.2% | — | — | |
| Q3 2014 | -0.2% | — | — | |
| Q2 2014 | -0.1% | — | — | |
| Q1 2014 | -3.5% | — | — | |
| Q4 2013 | -0.2% | — | — | |
| Q2 2013 | -1.8% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q4 2012 | +2.5% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q3 2012 | +1.3% | — | — | |
| Q2 2011 | +1.5% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2010 | +0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro